Ann: Updated Strategy and Investor Presentation, page-399

The P1a/b trial will be accepting any persons with a solid tumour that will be treated with an anthracycline (doxo/epi/daunorubicin). RAC have the confidence to accept any cancer types because of the wide efficacy seen in the Oncolines screening. 113 of the 143 cell lines showed potent anticancer activity, 86% of lines improved over dox alone - and importantly, no evidence of Bisantrene having 'negative synergy'.

In addition, the primary end point is not how the cancer responds to treatment. It's the effect of treatment on VO_2peak. Hopefully we will get signals of anticancer efficacy from those participants who have cancers sensitive to Bisantrene - but another function of this study is to let the drug tell us what cancers respond well, not the other way around. There's an element of chance as to what cancer types will be enrolled; ideally, we'll have multiple breast cancer patients and a spread of at least a dozen other indications.